赛伦生物：公司将结合自身发展需求及外部环境条件，持续关注并积极寻求优质的并购标的

Group 1 - The core viewpoint of the article highlights that the company's fourth-quarter revenue was low, which negatively impacted its quarterly profit due to the seasonal nature of its main products, antivenom and tetanus immunoglobulin [1] - The company noted that the incidence rates of snake bites and trauma are significantly higher in summer, leading to larger sales volumes in the second and third quarters, while the first and fourth quarters see lower sales [1] - The company is actively seeking quality acquisition targets to promote its external growth strategy, aligning with its development needs and external environmental conditions [1] Group 2 - The company emphasizes its commitment to adhering to information disclosure regulations and will fulfill its disclosure obligations if there are clear acquisition plans that meet the disclosure standards [1] - Relevant information regarding acquisitions will be based on the company's official announcements [1]